Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jon Pritchard

Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma

New England Journal of Medicine

Medicine

2009

English

Related publications

Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas.

Journal of Clinical Oncology

English

Cisplatin, Doxorubicin, and Cyclophosphamide Plus Thoracic Radiation Therapy for Limited-Stage Unresectable Thymoma: An Intergroup Trial.

Journal of Clinical Oncology

English

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer

Cancer Research and Treatment

Cancer Research

Oncology

2019

English

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Research in Oncology

2011

English

P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Journal of Thoracic Oncology

English

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only Against Cisplatin

PLoS ONE

Multidisciplinary

2013

English

Sequential Methotrexate and 5-Fluorouracil, Doxorubicin, and Cisplatin for Advanced Urothelial Cancer

Japanese Journal of Urology

Urology

1992

English

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

English

Systemic Complications of the Bidirectional Intraoperative Chemotherapy With Intravenous Ifosfamide and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Using Cisplatin Plus Doxorubicin

Pleura and Peritoneum

Internal Medicine

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jon Pritchard

Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma

Related publications

Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas.

Cisplatin, Doxorubicin, and Cyclophosphamide Plus Thoracic Radiation Therapy for Limited-Stage Unresectable Thymoma: An Intergroup Trial.

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only Against Cisplatin

Sequential Methotrexate and 5-Fluorouracil, Doxorubicin, and Cisplatin for Advanced Urothelial Cancer

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

Systemic Complications of the Bidirectional Intraoperative Chemotherapy With Intravenous Ifosfamide and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Using Cisplatin Plus Doxorubicin